Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers of Omalizumab Response in CIU
NCT02814630Completed
- Sponsor
- Airways Clinical Research Centers
- Start
- Sep 2016
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of omalizumab in chronic idiopathic urticaria (CIU), sponsored by Airways Clinical Research Centers. Primary endpoint: miRNAs in the blood differentially expressed after treatment with Xolair® at 12 weeks. Started Sep 2016; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on NCT02814630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02814630.